Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Academic Medical Organization of Southwestern Ontario | OTHER |
| Canadian Cardiovascular Society | OTHER |
| Stanford University | OTHER |
| Greenstone Biosciences |
Not provided
Not provided
Not provided
Not provided
Cannabis is commonly used globally. It is associated with psychiatric problems, but the effects on the cardiovascular system are unclear. In this project, the investigators plan to study the effects of cannabis on the cardiovascular system. This will be done by using a non-invasive test to measure blood vessel function and by using blood samples to measure inflammation. As a control for this project, the investigators would like to test the blood vessel function and inflammation levels of participants who do not use cannabis. This study will provide important information on the long term cardiovascular effects of cannabis.
Cannabis is the most commonly used illicit drug in the world, but the investigators do not know the long-term effects on the cardiovascular system in humans. The investigators have data from cell culture and small animal studies that cannabis is toxic to the cardiovascular system. Recently legalized in Canada, the long-term effects of cannabis use on the cardiovascular system may not be apparent for several decades. The purpose of this study is to test the effect of cannabis use on the vascular system. Using a non-invasive test of vascular function, the investigators would like to assess the effects of cannabis on chronic cannabis users. The investigators would also like to test if cannabis use by smoking and/or vaping causes adverse cardiovascular effects acutely. Lastly, the investigators would like to test blood from chronic cannabis users for inflammatory cytokines, which could further support our hypothesis that cannabis damages the cardiovascular system via inflammation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic Cannabis Cohort | For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:
For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude cannabis users:
|
| |
| Control Cohort | For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:
For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude participants:
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chronic Cannabis use | Other | The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Inflammation | The investigators will measure the concentration of inflammatory cytokines using an Olink for chronic cannabis users and the control group. | Baseline measurement. |
| Endothelial function | The investigators will measure the reactive hyperaemia index (RHI) using an EndPAT device for both groups. | Baseline measurement. |
| Measure | Description | Time Frame |
|---|---|---|
| Cholesterol Level | The investigators will measure lipid profile (total cholesterol, LDL, HDL, ratio) for both groups. | Baseline measurement. |
| BMI | The investigators will measure body-mass index or both groups. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The investigators plan to recruit participants from the London Health Sciences Centre HIV clinic and chronic pain clinic who use cannabis for medicinal purposes.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mark Chandy, MD, PhD | Contact | 5196612111 | mark.chandy@lhsc.on.ca | |
| Kerry-Ann Nakreiko, PhD | Contact | 5196612111 | 80249 | Kerry-Ann.Nakrieko@lhsc.on.ca |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| London Regional Health Science Centre | Recruiting | London | Ontario | N6A 5A5 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D007249 | Inflammation |
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
The investigators would like to test blood and vascular function of chronic cannabis users for signs of vascular dysfunction. The investigators e will obtain blood from a single blood draw using EDTA tubes. The investigators will separate into plasma, red blood cells, and white blood cells. The investigators will test the plasma from control and chronic cannabis users with a lipid panel, complete metabolic panel, HgbA1c, fasting glucose, and Olink inflammation panel. The investigators will retain unused plasma and peripheral blood mononuclear cells for future studies.
| Baseline measurement. |
| Blood pressure | The investigators will measure baseline blood pressure for both groups. | Baseline measurement. |
| D014652 | Vascular Diseases |